Dexmedetomidine produces its neuroprotective effect via the α2A-adrenoceptor subtype
- 11 October 2004
- journal article
- research article
- Published by Elsevier BV in European Journal of Pharmacology
- Vol. 502 (1-2), 87-97
- https://doi.org/10.1016/j.ejphar.2004.08.044
Abstract
No abstract availableKeywords
This publication has 50 references indexed in Scilit:
- The Effect of the α2-Agonist Dexmedetomidine and the N-Methyl-d-Aspartate Antagonist S(+)-Ketamine on the Expression of Apoptosis-Regulating Proteins After Incomplete Cerebral Ischemia and Reperfusion in RatsAnesthesia & Analgesia, 2003
- Hyperbaric oxygenation prevented brain injury induced by hypoxia–ischemia in a neonatal rat modelBrain Research, 2002
- Antinociceptive Effect of Dexmedetomidine, an Alpha-2 Adrenoceptor Agonist, on the Formalin Test in Newborn Fischer RatsAnesthesiology, 2002
- Alpha-adrenoceptor subtypesPharmacological Research, 2001
- Nitric Oxide Mediates Cerebral Ischemic Tolerance in a Neonatal Rat Model of Hypoxic PreconditioningJournal of Cerebral Blood Flow & Metabolism, 1999
- α2A- But not α2B/C-adrenoceptors modulate noradrenaline release in rat locus coeruleus: voltammetric dataEuropean Journal of Pharmacology, 1999
- Subtypes of functional α1- and α2-adrenoceptorsEuropean Journal of Pharmacology, 1998
- Evaluation of brain damage in a rat model of neonatal hypoxic-ischemiaJournal of Neuroscience Methods, 1990
- Intra-ischemic extracellular release of dopamine and glutamate is associated with striatal vulnerability to ischemiaNeuroscience Letters, 1988
- Glutamate neurotoxicity in cortical cell cultureJournal of Neuroscience, 1987